DotBio's modular human dAb platform generates and tests thousands of multi-functional antibody candidates preclinically — selecting only the best for the clinic.
Fully human, superstable VH domain antibodies generated entirely in vitro. Patent granted in US, EU & Japan. Low immunogenicity, high manufacturability — 5–10 g/L yields.
Disulfide-free intracellular domain antibodies that remain stable inside cells — targeting previously "undruggable" intracellular proteins like KRAS, eIF4E, and the full RAS/MAPK pathway.
Targeted engineered virus-like particles that deliver iDotBodies directly into cancer cells via membrane fusion — bypassing endosomal degradation for true intracellular protein delivery.
DotBio screened hundreds of bi-specific candidates preclinically. The cancer cell killing scores predicted — with striking accuracy — which molecules would succeed or fail in the clinic.
In 2022, DotBio out-licensed its anti-VEGF DotBody module to Junshi Biosciences (TopAlliance). Junshi built JS207 — a PD1 × VEGFA bispecific — around this module and advanced it into Phase II clinical trials. The strong interim results validate both the biology and DotBio's module quality.
JS207 is Junshi / TopAlliance's program. DotBio out-licensed its anti-VEGF DotBody module, which forms the backbone of JS207. Data presented at AACR 2026.
Read the News →A tri-specific antibody targeting PDL1 × TIGIT with a proprietary "dead" IL2 tether — selectively reactivating exhausted CD8+ T-cells in the tumor microenvironment while avoiding systemic toxicity.
DotBio's platform and module library are available for licensing, co-development, NewCo formation, and out-licensing. We have validated modules against 40+ targets and can generate new ones in ~4 months.
License DotBody technology to accelerate your pipeline
License validated clinical-stage or preclinical assets
Joint development of bi- or tri-specific assets against your targets
Form a new entity around a specific indication or asset
Building on USD 10.4M raised to date and deals worth over USD 200M, DotBio is raising a USD 20M Series A to advance DB007 to Phase I, validate intracellular platform in animals, and establish China presence.